Chakraborty Binita, Byemerwa Jovita, Krebs Taylor, Lim Felicia, Chang Ching-Yi, McDonnell Donald P
Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.
Known Medicine, Salt Lake City, UT 84108, USA.
Endocr Rev. 2023 Jan 12;44(1):117-141. doi: 10.1210/endrev/bnac017.
The immune system functions in a sexually dimorphic manner, with females exhibiting more robust immune responses than males. However, how female sex hormones affect immune function in normal homeostasis and in autoimmunity is poorly understood. In this review, we discuss how estrogens affect innate and adaptive immune cell activity and how dysregulation of estrogen signaling underlies the pathobiology of some autoimmune diseases and cancers. The potential roles of the major circulating estrogens, and each of the 3 estrogen receptors (ERα, ERβ, and G-protein coupled receptor) in the regulation of the activity of different immune cells are considered. This provides the framework for a discussion of the impact of ER modulators (aromatase inhibitors, selective estrogen receptor modulators, and selective estrogen receptor downregulators) on immunity. Synthesis of this information is timely given the considerable interest of late in defining the mechanistic basis of sex-biased responses/outcomes in patients with different cancers treated with immune checkpoint blockade. It will also be instructive with respect to the further development of ER modulators that modulate immunity in a therapeutically useful manner.
免疫系统以性别二态性方式发挥作用,雌性比雄性表现出更强的免疫反应。然而,雌性性激素如何在正常稳态和自身免疫中影响免疫功能却知之甚少。在这篇综述中,我们讨论雌激素如何影响先天性和适应性免疫细胞活性,以及雌激素信号失调如何成为某些自身免疫性疾病和癌症病理生物学的基础。我们考虑了主要循环雌激素以及三种雌激素受体(ERα、ERβ和G蛋白偶联受体)在调节不同免疫细胞活性中的潜在作用。这为讨论雌激素调节剂(芳香化酶抑制剂、选择性雌激素受体调节剂和选择性雌激素受体下调剂)对免疫的影响提供了框架。鉴于最近人们对确定接受免疫检查点阻断治疗的不同癌症患者中性别偏倚反应/结果的机制基础有相当大的兴趣,综合这些信息很及时。这对于以治疗有用的方式调节免疫的雌激素调节剂的进一步开发也将具有指导意义。